Health and Fitness Health and Fitness
Mon, March 7, 2011
Sat, March 5, 2011
Fri, March 4, 2011
Thu, March 3, 2011
Wed, March 2, 2011
[ Wed, Mar 02nd 2011 ] - Market Wire
BURCON AMENDS LETTER OF INTENT
Tue, March 1, 2011
Mon, February 28, 2011
Sun, February 27, 2011
Fri, February 25, 2011
Thu, February 24, 2011
Wed, February 23, 2011
Tue, February 22, 2011
[ Tue, Feb 22nd 2011 ] - Market Wire
PROTOX APPOINTS NEW DIRECTORS
Mon, February 21, 2011
Sun, February 20, 2011
Fri, February 18, 2011
Thu, February 17, 2011

Cerus to Release Fourth Quarter and Year-End 2010 Results on March 3, 2011


//health-fitness.news-articles.net/content/2011/ .. r-and-year-end-2010-results-on-march-3-2011.html
Published in Health and Fitness on Friday, February 25th 2011 at 5:45 GMT by Market Wire   Print publication without navigation


CONCORD, Calif.--([ BUSINESS WIRE ])--Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and year-end 2010 financial results will be released on Thursday, March 3, 2011, after the close of the stock market. The company will host a conference call and webcast at 4:15 p.m. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the Cerus web site at [ http://investor.cerus.com ]. Alternatively, you may access the live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549 (international).

A replay will be available on the companya™s web site, or by dialing 800-642-1687 (U.S.) or 706-645-9291 (international) and entering conference ID number 47634450. The replay will be available approximately three hours after the call through March 18, 2011.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development. See [ http://www.cerus.com ] for more information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.


Publication Contributing Sources